This hypothesis is consistent with the finding that overall survival of the patients treated with platinum-doublet chemotherapy as the first line treatment is not significantly different from that of patients treated with front-line EGFR-TKI, provided that the cross-over was high enough in patients with lung cancer harboring EGFR mutation [2,3]. The gene discussed is EGFR; the disease is lung cancer.